Status:

UNKNOWN

Excess Risk of Morbi-mortality Due to COVID-19 in Patients With Cancer

Lead Sponsor:

Hospices Civils de Lyon

Conditions:

COVID, Cancer

Eligibility:

All Genders

18+ years

Brief Summary

Context: Based on currently available data, most of national health authorities and consensus expert groups have written guidelines for the management of cancer patients in the context of COVID. Howe...

Eligibility Criteria

Inclusion

  • EXPOSED PATIENTS:
  • Age \> 18 years old
  • Patients with a confirmed diagnosis of solid or hematologic cancer
  • Patients who received their last anticancer treatment (surgery, systemic treatments or other localized treatment) in the past 5 years before SARS-CoV-2 infection
  • Positive laboratory test (RT-PCR) proving the SARS-CoV-2 infection
  • Patients hospitalized in one of the participating centers because of the SARS-CoV-2 infection
  • Patients who are not opposed in participating to the ONCOVID-AURA study
  • CONTROL PATIENTS:
  • Age \> 18 years old
  • Patients who have no cancer (neither solid nor hematologic tumors) or patients who received their last anticancer treatments more than five years before the SARS-CoV-2 infection
  • Positive laboratory test (RT-PCR) proving the SARS-CoV-2 infection
  • Patients hospitalized in one of the participating centers because of the SARS-CoV-2 infection
  • Patients who are not opposed in participating to the ONCOVID-AURA study

Exclusion

  • none

Key Trial Info

Start Date :

June 15 2020

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

February 15 2021

Estimated Enrollment :

600 Patients enrolled

Trial Details

Trial ID

NCT04457570

Start Date

June 15 2020

End Date

February 15 2021

Last Update

July 7 2020

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Centre de lutte contre le Cancer JEAN PERRIN

Clermont-Ferrand, France

2

Centre Hospitalier Uniersitaire de Clermont-Ferrand

Clermont-Ferrand, France

3

Centre Leon Berard

Lyon, France

4

Centre Hospitalier Universitaire de St Etienne

Saint-Etienne, France

Excess Risk of Morbi-mortality Due to COVID-19 in Patients With Cancer | DecenTrialz